Callan Family Office LLC Has $3.64 Million Stake in Amgen Inc. (NASDAQ:AMGN)

Callan Family Office LLC increased its stake in Amgen Inc. (NASDAQ:AMGN) by 550.4% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 13,945 shares of the medical research company’s stock after purchasing an additional 11,801 shares during the period. Callan Family Office LLC’s holdings in Amgen were worth $3,635,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. Capital Performance Advisors LLP acquired a new position in shares of Amgen during the third quarter worth about $25,000. Centricity Wealth Management LLC acquired a new stake in Amgen in the 4th quarter valued at approximately $25,000. Legacy Investment Solutions LLC bought a new stake in Amgen in the 3rd quarter valued at approximately $29,000. Synergy Investment Management LLC acquired a new position in Amgen during the 4th quarter worth approximately $34,000. Finally, Heck Capital Advisors LLC bought a new position in shares of Amgen during the 4th quarter worth approximately $36,000. Institutional investors own 76.50% of the company’s stock.

Insider Buying and Selling

In other news, SVP Nancy A. Grygiel sold 1,589 shares of Amgen stock in a transaction on Wednesday, February 5th. The stock was sold at an average price of $304.47, for a total transaction of $483,802.83. Following the completion of the sale, the senior vice president now owns 7,210 shares of the company’s stock, valued at approximately $2,195,228.70. This trade represents a 18.06 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Murdo Gordon sold 8,771 shares of the business’s stock in a transaction dated Tuesday, February 11th. The shares were sold at an average price of $294.79, for a total transaction of $2,585,603.09. Following the completion of the sale, the executive vice president now directly owns 44,186 shares of the company’s stock, valued at approximately $13,025,590.94. The trade was a 16.56 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 69,341 shares of company stock valued at $20,644,335. Insiders own 0.69% of the company’s stock.

Analyst Ratings Changes

AMGN has been the topic of a number of research reports. Royal Bank of Canada reissued an “outperform” rating and issued a $324.00 price objective on shares of Amgen in a research report on Friday, January 24th. Jefferies Financial Group reiterated a “buy” rating and issued a $380.00 price target on shares of Amgen in a research note on Tuesday, November 12th. Wells Fargo & Company restated an “equal weight” rating on shares of Amgen in a research note on Wednesday, February 5th. Deutsche Bank Aktiengesellschaft decreased their price objective on Amgen from $305.00 to $285.00 in a report on Wednesday, November 27th. Finally, William Blair reiterated an “outperform” rating on shares of Amgen in a report on Tuesday, November 12th. Two equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Amgen presently has a consensus rating of “Hold” and a consensus target price of $314.95.

Amgen Price Performance

Shares of AMGN opened at $317.82 on Friday. The company’s 50-day moving average is $284.89 and its 200-day moving average is $299.91. The company has a debt-to-equity ratio of 9.62, a current ratio of 1.26 and a quick ratio of 0.95. The firm has a market capitalization of $170.73 billion, a PE ratio of 42.10, a PEG ratio of 2.63 and a beta of 0.56. Amgen Inc. has a fifty-two week low of $253.30 and a fifty-two week high of $346.85.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share for the quarter, beating the consensus estimate of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%. Equities analysts forecast that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Friday, May 16th will be issued a dividend of $2.38 per share. The ex-dividend date is Friday, May 16th. This represents a $9.52 annualized dividend and a yield of 3.00%. Amgen’s payout ratio is currently 126.09%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.